Aiforia announces the CE-IVD mark of its Aiforia® Clinical AI Model for Lung Cancer; PD-L1 for assisting pathologists in the fast and accurate primary diagnosis of lung cancer. This latest AI model expands Aiforia’s portfolio of clinical...

The CE-IVD marked AI model for Ki67 is the first model to be released as part of the Aiforia Clinical Suite for Breast Cancer, supporting pathologists in cancer diagnosis. First-of-its kind diagnostic tool Aiforia today announced the CE-IVD...

Aiforia announced the release of Velocity, the latest software release of tools, features and a new product, built upon the current scalable cloud platform, that allow medical and scientific experts to speed-up and simplify image analysis,...

Promega Corporation intends to seek FDA approval and CE-IVD marking for a commercially available Microsatellite Instability (MSI) assay to assist oncologists and pathologists in determining colorectal cancer decisions. The current Promega...

HalioDx receives CLIA Compliance for its laboratory based in Marseille Immunoscore® Colon, is now available to US patients in selected states with a turnaround time of 10 days Marseille, June 21, 2017 - HalioDx announced today that...

Carlsbad, CA – January 11, 2017 – Applied Spectral Imaging (ASI) announced today that its GenASIsTM  applications comply with CE-IVD requirements under the European Directive on In Vitro Diagnostic Medical Devices, for automated analysis...